Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST: niraparib versus placebo in ctDNA-positive HER2-negative BRCA-mutated or triple-negative breast cancer after definitive therapy
2023-504454-35-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and triple-negative breast cancer (TNBC) comparing Niraparib with Placebo (2 arms). Primary endpoint: Safety. Planned start Jun 2021; status: authorised.
02
Drugs
niraparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-504454-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504454-35-00.